Drug interaction between infliximab and azathioprine in patients with Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 18, Issue 9, 2003, Pages 917-925

  Roblin, X ^a   Serre Debeauvais, F ^b   Phelip, J M ^a   Bessard, G ^b   Bonaz, B ^a,b  

^a Dept d'Hépato Gastroenterol ^*  (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; INFLIXIMAB; MESALAZINE; METHOTREXATE; NUCLEOTIDE DERIVATIVE; PREDNISONE; STEROID; TIOGUANINE;

ADULT; ANUS FISTULA; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; DRUG FEVER; DRUG INFUSION; DRUG TOLERABILITY; ERYTHROCYTE; FEMALE; HUMAN; INFECTION; LEUKOCYTE COUNT; MALAISE; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES; AZATHIOPRINE; CROHN DISEASE; DRUG INTERACTIONS; FEMALE; GASTROINTESTINAL AGENTS; GUANINE NUCLEOTIDES; HUMANS; LEUKOCYTE COUNT; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; THIONUCLEOTIDES; TREATMENT OUTCOME;

EID: 0242383310     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01778.x     Document Type: Article

References (35)

1. Arend WP. Inhibiting the effects of cytokines in human diseases. Adv Intern Med 1995; 40: 365-94.
2. Targan SR, Hanauer SB, Sander JH, et al., for the Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997; 337: 1029-35.
3. Present DH, Rutgerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405.
4. Maini RN, Taylor PC, Paleolog E, et al. Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis. Ann Rheum Dis 1999; 58(Suppl. 1): I 56-60.
5. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000; 343: 1594-602.
6. Weinblatt ME. Methotrexate. In: Kelley WN, Harris ED, eds. Textbook of Rheumatology. Boston: W.B. Saunders, 1993: 767-76.
7. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine: a long-term randomized, double blind study. N Engl J Med 1980; 302: 981-7.
8. Elion GB. The pharmacology of azathioprine. Ann NY Acad Sci 1993; 685: 401-7.
9. Tidd DM, Paterson ARP. A biochemical mechanism for delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 1974; 34: 738-46.
10. Weinshilboum RM, Siadek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651-61.
11. Cuffari C, Theoret Y, Lathour S. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996; 39: 401-6.
12. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48: 642-6.
13. Dubinski MC, Lamothe S, Hy S, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-13.
14. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-64.
15. Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P. Chimeric anti-tumor necrosis factor-alpha monoclonal anti-body treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000; 27: 841-50.
16. Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet 2001; 40: 723-51.
17. Bokkerink JP, Bakker MA, Hulscher TW, et al. Sequence-, time-and dose-dependent synergism of methotrexate and 6-mercaptopurine in malignant human T-lymphoblasts. Biochem Pharmacol 1986; 35: 3549-55.
18. Dervieux T, Hancock M, Evans W, Pui CH, Relling MV. Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine. Leukemia 2002; 16: 209-12.
19. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980; 1: 514.
20. Lennard L. Clinical implications of thiopurine methyltransferase - optimization of drug dosage and potential drug interactions. Ther Drug Monit 1998; 20: 527-31.
21. Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001; 49: 656-64.
22. Lennard L, Maddocks JL. Assay of 6-thioguanine nucleotide, a major metabolite of azathioprine, 6-mercaptopurine and 6-thioguanine, in human red blood cells. J Pharm Pharmacol 1983; 35: 15-8.
23. Rossi AM, Bianchi M, Garnieri C, Barale R, Pacifici GM. Genotype-phenotype correlation for thiopurine S-methyltransferase healthy Italian subjects. Eur J Clin Pharmacol 2001; 57: 51-4.
24. Zietkiewicz E, Yotova V, Jarnik M, et al. Nuclear DNA diversity in worldwide distributed human populations. Gene 1997; 205: 161-71.
25. Masson E, Relling MV, Synold TW, et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. J Clin Invest 1996; 97: 73-80.
26. Balis FM, Holcenberg JS, Zimm S, et al. The effect of methotrexate on the bioavailability of oral 6-mercaptopurine. Clin Pharmacol Ther 1987; 41: 384-7.
27. Serre-Debeauvais F, Zaoui Ph, Egelhoffer H, et al. Pharmacological monitoring of azathioprine therapy. In: Touraine JL, Traeger J, Betuel H, eds. Transplantation and Clinical Immunology XXIV. Amsterdam: Publisher. 1992: 211-16.
28. Lennard L, Davies HA, Lilleyman JS. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia? Br J Cancer 1993; 68: 186-90.
29. Erb N, Harms DO, Janka-Schaub G. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine. Cancer Chemother Pharmacol 1998; 42: 266-72.
30. Bonaz B, Boitard J, Marteau P, et al. Thioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. Aliment Pharmacol Ther 2003; 18: 401-8.
31. Hurlimann D, Forster A, Noll G, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106: 2184-7.
32. Farrel RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomised controlled trial. Gastroenterology 2003; 124: 1140-5.
33. Bernstein CN, Artinian L, Anton PA, Shanahan F. Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity. Dig Dis Sci 1994; 39: 1638-41.
34. Parsi MA, Achkar J-P, Richardson S, et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002; 123: 701-13.
35. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomised trial. Lancet 2002; 359: 1541-9.